The Role of COX-2 in Oral Cancer Development, and Chemoprevention/ Treatment of Oral Cancer by Selective COX-2 Inhibitors

Author(s): Z. Wang

Journal Name: Current Pharmaceutical Design

Volume 11 , Issue 14 , 2005

Become EABM
Become Reviewer

Abstract:

Oral cancer is challenging for clinicians due to its high mortality and increasing incidence rate. Cyclooxygenase-2 (COX-2) is extensively expressed in oral cancer and oral premalignant lesions and seems to be enhanced specifically in high-risk oral lesions. Mounting evidence suggests that these inhibitors may represent a promising approach for chemoprevention or treatment of oral cancer. This review reports on Medline and PubMed literature searches of published articles from 1995 to 2003. Our purpose is to provide a comprehensive examination and discussion of the potential role of COX-2 in oral cancer development and the use of COX-2 inhibitors for oral cancer chemoprevention or treatment. The data in the literature strongly indicate that COX-2 is significantly upregulated in oral cancer and premalignant lesions, and we believe that inhibition of COX-2 would suppress development of oral lesions by affecting several pathways of oral carcinogenesis. Therefore, the COX-2 inhibitors should be investigated as a new treatment, particularly new chemoprevention agents, for patients who are at high risk for developing oral cancer.

Keywords: cyclooxygenase, selective cox-2 inhibitors, oral cancer, chemoprevention

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 11
ISSUE: 14
Year: 2005
Page: [1771 - 1777]
Pages: 7
DOI: 10.2174/1381612053764887
Price: $65

Article Metrics

PDF: 4